Lancet, Oct 2024 "Cardiac manifestations and outcomes of COVID-19 vaccine-associated myocarditis in the young in the USA: longitudinal results from the Myocarditis After COVID Vaccination (MACiV) multicenter study"
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00388-2/fulltext
Heart damage often doesn't kill them - yet it lasts.
Myocardial injury at initial presentation and its persistence at follow up, despite a mild initial course and favorable mid-term clinical outcome, warrants continued clinical surveillance and long-term studies in affected patients with C-VAM (COVID-19 vaccine-associated myocarditis).
at a median follow up of 159 days (IQR 78–253 days). Five patients (5%) among those that continued to be LGE positive at follow-up were reported to have worsening of LGE, including three patients with recurrence of cardiac symptoms including chest pain, palpitations, dizziness or fatigue. One patient required re-hospitalization with elevated troponin as described above, two had T-wave inversions on follow-up ECGs and one patient experienced ventricular tachycardia
5e6efe3c-0f0e-411b-b208-540b729d467a-gr5.jpg
